MDXG vs VCEL
MDXG: MiMedx develops and distributes advanced wound care biologics including human placental allografts and expanding xenograft/collagen products to treat chronic and hard-to-heal wounds across surgical and clinical settings. VCEL: Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and Epicel for severe burns.
Side-by-side fundamentals
| Metric | MDXG | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.17 | $44.56 | |
| Market cap as of 2026-07-23 | $621M | $2.4B | |
| P/E as of 2026-07-23 | 20.23 | 109.79 | MDXG lower |
| PEG as of 2026-07-23 | n/a | 0.12 | |
| Net margin as of 2026-07-23 | +7.9% | +7.3% | MDXG higher |
| Gross margin as of 2026-07-23 | +81.0% | +74.8% | MDXG higher |
| Operating margin as of 2026-07-23 | +10.2% | +5.4% | MDXG higher |
| ROE as of 2026-07-23 | +12.9% | +6.4% | MDXG higher |
| ROA as of 2026-07-23 | +9.7% | +4.6% | MDXG higher |
| Debt / equity as of 2026-07-23 | 0.07 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.5% | +22.4% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | +16.1% | +18.9% | VCEL higher |
| Beta as of 2026-07-23 | 1.47 | 1.08 | |
| 1-year return as of 2026-07-22 close | -35.0% | +17.3% | VCEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.